HLS Therapeutics Inc
TSX:HLS
Operating Margin
HLS Therapeutics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CA |
|
HLS Therapeutics Inc
TSX:HLS
|
155.5m CAD |
-8%
|
|
| US |
|
Mckesson Corp
NYSE:MCK
|
88.7B USD |
1%
|
|
| US |
|
Cencora Inc
NYSE:COR
|
56.8B USD |
1%
|
|
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
56.9B USD |
1%
|
|
| US |
|
Cardinal Health Inc
NYSE:CAH
|
38.1B USD |
1%
|
|
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.4B AUD |
0%
|
|
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
78.6B CNY |
11%
|
|
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
70.4B CNY |
3%
|
|
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW |
9%
|
|
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.4B USD |
6%
|
|
| AU |
E
|
EBOS Group Ltd
OTC:EBOSY
|
8.2B USD |
4%
|
HLS Therapeutics Inc
Glance View
HLS Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The firm is focused on developing clinically differentiated pharmaceutical products in the specialty central nervous system (CNS) and cardiovascular (CV) markets. Its products include Vascepa, Trinomia, Clozaril, CSAN Pronto, PERSERIS and MyCare Psychiatry/MyCare Insite. Its lead product, Clozaril, is an atypical antipsychotic indicated in the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules reduce the risk of cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina in statin-treated patients with elevated triglycerides.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on HLS Therapeutics Inc's most recent financial statements, the company has Operating Margin of -8.2%.
You don't have any saved screeners yet